Ownership Capital B.V. Cuts Stake in Insulet Corporation $PODD

Ownership Capital B.V. reduced its position in Insulet Corporation (NASDAQ:PODD) by 89.3% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 12,381 shares of the medical instruments supplier’s stock after selling 103,193 shares during the period. Insulet accounts for 2.2% of Ownership Capital B.V.’s portfolio, making the stock its 20th biggest position. Ownership Capital B.V.’s holdings in Insulet were worth $3,822,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PODD. True Wealth Design LLC raised its holdings in shares of Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 72 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 69 shares during the period. Trust Co. of Toledo NA OH bought a new position in shares of Insulet in the 2nd quarter worth $35,000. Whittier Trust Co. of Nevada Inc. raised its position in shares of Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 43 shares in the last quarter. Finally, Quent Capital LLC purchased a new position in Insulet in the third quarter valued at about $49,000.

Insulet Price Performance

Shares of PODD opened at $271.31 on Tuesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. The company’s fifty day moving average price is $297.35 and its 200-day moving average price is $310.15. Insulet Corporation has a 1-year low of $230.05 and a 1-year high of $354.88. The firm has a market capitalization of $19.09 billion, a PE ratio of 78.64, a price-to-earnings-growth ratio of 1.51 and a beta of 1.40.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The firm’s revenue was up 29.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.08 EPS. On average, equities research analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on PODD. BTIG Research increased their price target on shares of Insulet from $370.00 to $380.00 and gave the company a “buy” rating in a research report on Friday, November 21st. The Goldman Sachs Group reiterated a “buy” rating and set a $365.00 price objective on shares of Insulet in a research note on Friday, January 9th. Evercore ISI initiated coverage on shares of Insulet in a research report on Tuesday, December 16th. They set an “outperform” rating and a $370.00 target price for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a research report on Thursday. Finally, Wolfe Research boosted their target price on Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Twenty equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $379.10.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.